
March 2001 From Porter Novelli Application deadline extended for new AstraZeneca neurology, psychiatry awardsYoung minds program recognizes, supports future leaders 26 March 2001 -- AstraZeneca PLC announced today the extension of the application deadline to August 31, 2001 for proposal submissions for its international Young Minds in CNS Awards Program, which recognizes and promotes promising work from young physicians and investigators working in the central nervous system (CNS) therapeutic area. AstraZeneca created the Young Minds program to help foster scientific innovation and improve treatments of CNS diseases. The peer-reviewed program will award five US $20,000 unrestricted career development awards in October 2001 to support a range of activities including research, educational efforts, travel, salary support and materials. �Through the Young Minds in CNS Awards Program, AstraZeneca intends to help develop the careers of young physicians and investigators, which ultimately will enhance effectiveness of managing CNS patients and improving their quality of life,� said Ron Polinsky, M.D., Vice President, Global CNS Medical Director, AstraZeneca. Award proposals must demonstrate how winning a Young Minds in CNS Award will develop the applicant�s career. The awards will be made in the following disease categories: - Bipolar Disorder/Mania
- Depression
- Migraine
- Schizophrenia
- Stroke (acute)
In addition to participating in the award reception at a major neurology and/or psychiatry congress in 2001, AstraZeneca will sponsor recipients to attend an international CNS-related medical meeting in the United States or Europe in 2002. An independent steering committee representing distinguished experts in the CNS field was formed to develop the Young Minds in CNS Awards Program. As part of their commitment to this program, the steering committee will also review award applications and recommend those to be funded. Applications are available through the AstraZeneca corporate Web site at http://www.astrazeneca.com/youngminds/. AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of $15.8 billion and leading positions in cardiovascular, gastrointestinal, oncology, anaesthesia including pain management, central nervous system (CNS) and respiratory products. In CNS, AstraZeneca is dedicated to providing innovative medicines for the treatment of diseases where there is high unmet medical need. The company already markets drugs for the treatment of migraine (ZOMIG�) and schizophrenia (SEROQUEL�), and has an industry-leading R&D pipeline of several novel pharmacological approaches for the treatment of acute stroke, depression and anxiety and other key disease areas. Additional information on AstraZeneca is available on the company�s website, http://www.astrazeneca.com. Editor�s Note (Not For Publication): The Steering Committee includes: Dr. Bruce Dan, former Senior Editor of the Journal of the American Medical Association; Dr. Hans-Christopher Diener, Essen University, Essen, Germany; Dr. Dexter L. Morris, University of North Carolina, Chapel Hill, North Carolina; Dr. Gary E. Ruoff, West Side Family Medical Center, Kalamazoo, Michigan; and Dr. Tonmoy Sharma, Institute of Psychiatry, London, England.
|